Routine

Autosomal dominant polycystic kidney disease

Nephrology · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

The commonest inherited kidney disease, causing progressive cyst growth, hypertension and a march toward kidney failure, with important extrarenal features (liver cysts, intracranial aneurysms). Management controls blood pressure and, in rapid progressors, slows cyst growth with tolvaptan. First action: confirm with imaging and family history, and control blood pressure.

Red flags

  • Refer to nephrology for diagnosis, progression assessment and tolvaptan consideration
  • Urgent assessment for thunderclap headache (possible aneurysm rupture), cyst infection or significant haematuria
  • Transplant work-up as kidney failure approaches

Assessment

Investigations

  • Renal ultrasound (age-adjusted cyst criteria) or MRI; genetic testing where imaging is equivocal or for donor evaluation
  • Monitor eGFR, urine ACR and BP
  • Screen for intracranial aneurysm with MR angiography in those with a family history of aneurysm/SAH or high-risk occupations

Management

  • Strict blood-pressure control (ACEi/ARB first-line) and generous fluid intake
  • Tolvaptan (a vasopressin V2 antagonist) slows cyst growth and eGFR decline in adults at risk of rapid progression — monitor LFTs
  • Treat cyst infection/haemorrhage and stones; manage pain
  • Prepare for renal replacement therapy/transplantation as function declines; genetic counselling and family screening

Disposition

Refer to nephrology for diagnosis, progression assessment and tolvaptan consideration.

Complications & pitfalls

  • Progressive CKD to end-stage disease, resistant hypertension, cyst infection and haemorrhage, nephrolithiasis, and subarachnoid haemorrhage from a ruptured intracranial aneurysm

Exam pearls

  • A thunderclap headache in someone with ADPKD is a ruptured berry aneurysm until proven otherwise — image the head urgently, and screen for aneurysms in those with a positive family history.
  • Monitoring & follow-up: Regular BP, eGFR and ACR; total kidney volume on MRI helps assess progression risk. LFTs on tolvaptan. Family screening and counselling; targeted aneurysm surveillance in at-risk individuals.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.